Literature DB >> 18985367

CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.

Annegret Kuhn1, Stefan Beissert, Peter H Krammer.   

Abstract

Natural CD4(+)CD25(+) regulatory T cells (T(reg)) show a potent immunosuppressive function and contribute to immunologic self-tolerance by suppressing potentially auto-reactive T cells. Depletion of these cells leads to the induction of severe autoimmune diseases in animal models; more recently, several studies have also reported an impairment of T(reg) number and/or function in various human autoimmune diseases. For example, aberrant numbers of circulating CD4(+)CD25(+) T(reg) have been seen in patients with type I diabetes, mycosis fungoides, graft-versus-host-reaction, and rheumatoid arthritis. Moreover, increased numbers of functionally active CD4(+)CD25(+) T(reg) have been detected in the synovial fluid of patients with rheumatoid arthritis. In systemic lupus erythematosus (SLE), conflicting data on the role of CD4(+)CD25(+) T(reg) in human autoimmune diseases have been presented in the literature. Decreased numbers of peripheral blood T(reg) have been reported by most studies on SLE patients with active disease, but non-impaired or even increased CD4(+)CD25(+) T(reg) numbers have also been described. In addition, both deficient and normal suppressive capacity of isolated T(reg) have been observed in SLE. Analysis of CD4(+)FoxP3(+) T(reg) in skin lesions of patients with a primarily cutaneous manifestation of the disease showed a significant reduction in cell numbers as compared to other inflammatory skin diseases, suggesting the importance of analyzing T(reg) numbers in the affected tissue. In this review, we discuss the role of CD4(+)CD25(+) T(reg) in autoimmunity and recent published data on SLE. Furthermore, we highlight the need for additional studies that address specific gaps of knowledge regarding the pathophysiological mechanisms as well as the identification of future therapeutic strategies for autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985367     DOI: 10.1007/s00403-008-0891-9

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  35 in total

Review 1.  Natural regulatory T cells in autoimmunity.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Autoimmunity       Date:  2010-11-23       Impact factor: 2.815

2.  Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study.

Authors:  J Baraut; E I Grigore; F Jean-Louis; S H Khelifa; C Durand; F Verrecchia; D Farge; L Michel
Journal:  Bone Marrow Transplant       Date:  2013-12-23       Impact factor: 5.483

3.  The NZM2410-derived lupus susceptibility locus Sle2c1 increases Th17 polarization and induces nephritis in fas-deficient mice.

Authors:  Zhiwei Xu; Carla M Cuda; Byron P Croker; Laurence Morel
Journal:  Arthritis Rheum       Date:  2011-03

4.  Associations of rs4810485 and rs1883832 polymorphisms of CD40 gene with susceptibility and clinical findings of Behçet's disease.

Authors:  Esra Erkol İnal; Aydın Rüstemoğlu; Ahmet İnanır; Duygu Ekinci; Ülker Gül; Serbülent Yiğit; Ömer Ateş
Journal:  Rheumatol Int       Date:  2014-11-06       Impact factor: 2.631

5.  Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.

Authors:  Nicole L Regna; Cristen B Chafin; Sarah E Hammond; Abdul G Puthiyaveetil; David L Caudell; Christopher M Reilly
Journal:  Clin Immunol       Date:  2014-01-15       Impact factor: 3.969

6.  Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus.

Authors:  Mojtaba Habibagahi; Zahra Habibagahi; Mansooreh Jaberipour; Amir Aghdashi
Journal:  Rheumatol Int       Date:  2010-04-02       Impact factor: 2.631

Review 7.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

8.  Subpopulations of regulatory T cells in rheumatoid arthritis, systemic lupus erythematosus, and Behcet's disease.

Authors:  Jae-Ryong Kim; Jin-Nyeong Chae; Sang-Hyon Kim; Jung-Sook Ha
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

9.  Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome.

Authors:  Ester Rosári Raphaelli Dal Ben; Carine Hartmann do Prado; Talita Siara Almeida Baptista; Moisés Evandro Bauer; Henrique Luiz Staub
Journal:  J Clin Immunol       Date:  2013-01-29       Impact factor: 8.317

10.  Expression and significance of CD4(+)CD25(+)CD127(-) regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barré syndrome.

Authors:  Hao Wang; Li Li; Yin Zhang; Shu-Chao Pan; An-Qiang Chen; Wei-Dong Qian
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.